Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind Dose - Escalation, Randomized, Controlled, Phase I-II Trial to Evaluate Safety and Immunogenicity of Three Doses of Sabin-IPV and Adjuvanted Sabin-IPV in Healthy Infants

NCT01709071 is registered in ClinicalTrials.gov with Pauline Verdijk as lead sponsor.

NCT NCT01709071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01709071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind Dose - Escalation, Randomized, Controlled, Phase I-II Trial to Evaluate Safety and Immunogenicity of Three Doses of Sabin-IPV and Adjuvanted Sabin-IPV in Healthy Infants
Lead sponsor
Pauline Verdijk
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2012
Completion date
May 31, 2013
Enrollment
140 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

poliomyelitis